Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: A nationwide retrospective study

Masakatsu Hishizawa, Junya Kanda, Atae Utsunomiya, Shuichi Taniguchi, Tetsuya Eto, Yukiyoshi Moriuchi, Ryuji Tanosaki, Fumio Kawano, Yasushi Miyazaki, Masato Masuda, Koji Nagafuji, Masamichi Hara, Minoko Takanashi, Shunro Kai, Yoshiko Atsuta, Ritsuro Suzuki, Takakazu Kawase, Keitaro Matsuo, Tokiko Nagamura-Inoue, Shunichi KatoHisashi Sakamaki, Yasuo Morishima, Jun Okamura, Tatsuo Ichinohe, Takashi Uchiyama

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used as a curative option for adult T-cell leukemia (ATL), an intractable mature T-cell neoplasm causally linked with human T-cell leukemia virus type I (HTLV-I). We compared outcomes of 386 patients with ATL who underwent allogeneic HSCT using different graft sources: 154 received human leukocyte antigen (HLA)-matched related marrow or peripheral blood; 43 received HLA-mismatched related marrow or peripheral blood; 99 received unrelated marrow; 90 received single unit unrelated cord blood. After a median follow-up of 41 months (range, 1.5-102), 3-year overall survival for entire cohort was 33% (95% confidence interval, 28%-38%). Multivariable analysis revealed 4 recipient factors significantly associated with lower survival rates: older age (> 50 years), male sex, status other than complete remission, and use of unrelated cord blood compared with use of HLA-matched related grafts. Treatment-related mortality rate was higher among patients given cord blood transplants; disease-associated mortality was higher among male recipients or those given transplants not in remission. Among patients who received related transplants, donor HTLV-I seropositivity adversely affected disease-associated mortality. In conclusion, allogeneic HSCT using currently available graft source is an effective treatment in selected patients with ATL, although greater effort is warranted to reduce treatment-related mortality.

Original languageEnglish
Pages (from-to)1369-1376
Number of pages8
JournalBlood
Volume116
Issue number8
DOIs
Publication statusPublished - 2010 Aug 26
Externally publishedYes

Fingerprint

Adult T Cell Leukemia Lymphoma
T-cells
Hematopoietic Stem Cell Transplantation
Stem cells
Retrospective Studies
Blood
Transplants
HLA Antigens
Fetal Blood
Human T-lymphotropic virus 1
Grafts
Mortality
Bone Marrow
Viruses
Therapeutics
Survival Rate
Tissue Donors
Confidence Intervals
T-Lymphocytes
Survival

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Medicine(all)
  • Hematology
  • Cell Biology

Cite this

Hishizawa, M., Kanda, J., Utsunomiya, A., Taniguchi, S., Eto, T., Moriuchi, Y., ... Uchiyama, T. (2010). Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: A nationwide retrospective study. Blood, 116(8), 1369-1376. https://doi.org/10.1182/blood-2009-10-247510

Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia : A nationwide retrospective study. / Hishizawa, Masakatsu; Kanda, Junya; Utsunomiya, Atae; Taniguchi, Shuichi; Eto, Tetsuya; Moriuchi, Yukiyoshi; Tanosaki, Ryuji; Kawano, Fumio; Miyazaki, Yasushi; Masuda, Masato; Nagafuji, Koji; Hara, Masamichi; Takanashi, Minoko; Kai, Shunro; Atsuta, Yoshiko; Suzuki, Ritsuro; Kawase, Takakazu; Matsuo, Keitaro; Nagamura-Inoue, Tokiko; Kato, Shunichi; Sakamaki, Hisashi; Morishima, Yasuo; Okamura, Jun; Ichinohe, Tatsuo; Uchiyama, Takashi.

In: Blood, Vol. 116, No. 8, 26.08.2010, p. 1369-1376.

Research output: Contribution to journalArticle

Hishizawa, M, Kanda, J, Utsunomiya, A, Taniguchi, S, Eto, T, Moriuchi, Y, Tanosaki, R, Kawano, F, Miyazaki, Y, Masuda, M, Nagafuji, K, Hara, M, Takanashi, M, Kai, S, Atsuta, Y, Suzuki, R, Kawase, T, Matsuo, K, Nagamura-Inoue, T, Kato, S, Sakamaki, H, Morishima, Y, Okamura, J, Ichinohe, T & Uchiyama, T 2010, 'Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: A nationwide retrospective study', Blood, vol. 116, no. 8, pp. 1369-1376. https://doi.org/10.1182/blood-2009-10-247510
Hishizawa, Masakatsu ; Kanda, Junya ; Utsunomiya, Atae ; Taniguchi, Shuichi ; Eto, Tetsuya ; Moriuchi, Yukiyoshi ; Tanosaki, Ryuji ; Kawano, Fumio ; Miyazaki, Yasushi ; Masuda, Masato ; Nagafuji, Koji ; Hara, Masamichi ; Takanashi, Minoko ; Kai, Shunro ; Atsuta, Yoshiko ; Suzuki, Ritsuro ; Kawase, Takakazu ; Matsuo, Keitaro ; Nagamura-Inoue, Tokiko ; Kato, Shunichi ; Sakamaki, Hisashi ; Morishima, Yasuo ; Okamura, Jun ; Ichinohe, Tatsuo ; Uchiyama, Takashi. / Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia : A nationwide retrospective study. In: Blood. 2010 ; Vol. 116, No. 8. pp. 1369-1376.
@article{939a5f2d6e1848a287307fa467f63c3b,
title = "Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: A nationwide retrospective study",
abstract = "Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used as a curative option for adult T-cell leukemia (ATL), an intractable mature T-cell neoplasm causally linked with human T-cell leukemia virus type I (HTLV-I). We compared outcomes of 386 patients with ATL who underwent allogeneic HSCT using different graft sources: 154 received human leukocyte antigen (HLA)-matched related marrow or peripheral blood; 43 received HLA-mismatched related marrow or peripheral blood; 99 received unrelated marrow; 90 received single unit unrelated cord blood. After a median follow-up of 41 months (range, 1.5-102), 3-year overall survival for entire cohort was 33{\%} (95{\%} confidence interval, 28{\%}-38{\%}). Multivariable analysis revealed 4 recipient factors significantly associated with lower survival rates: older age (> 50 years), male sex, status other than complete remission, and use of unrelated cord blood compared with use of HLA-matched related grafts. Treatment-related mortality rate was higher among patients given cord blood transplants; disease-associated mortality was higher among male recipients or those given transplants not in remission. Among patients who received related transplants, donor HTLV-I seropositivity adversely affected disease-associated mortality. In conclusion, allogeneic HSCT using currently available graft source is an effective treatment in selected patients with ATL, although greater effort is warranted to reduce treatment-related mortality.",
author = "Masakatsu Hishizawa and Junya Kanda and Atae Utsunomiya and Shuichi Taniguchi and Tetsuya Eto and Yukiyoshi Moriuchi and Ryuji Tanosaki and Fumio Kawano and Yasushi Miyazaki and Masato Masuda and Koji Nagafuji and Masamichi Hara and Minoko Takanashi and Shunro Kai and Yoshiko Atsuta and Ritsuro Suzuki and Takakazu Kawase and Keitaro Matsuo and Tokiko Nagamura-Inoue and Shunichi Kato and Hisashi Sakamaki and Yasuo Morishima and Jun Okamura and Tatsuo Ichinohe and Takashi Uchiyama",
year = "2010",
month = "8",
day = "26",
doi = "10.1182/blood-2009-10-247510",
language = "English",
volume = "116",
pages = "1369--1376",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia

T2 - A nationwide retrospective study

AU - Hishizawa, Masakatsu

AU - Kanda, Junya

AU - Utsunomiya, Atae

AU - Taniguchi, Shuichi

AU - Eto, Tetsuya

AU - Moriuchi, Yukiyoshi

AU - Tanosaki, Ryuji

AU - Kawano, Fumio

AU - Miyazaki, Yasushi

AU - Masuda, Masato

AU - Nagafuji, Koji

AU - Hara, Masamichi

AU - Takanashi, Minoko

AU - Kai, Shunro

AU - Atsuta, Yoshiko

AU - Suzuki, Ritsuro

AU - Kawase, Takakazu

AU - Matsuo, Keitaro

AU - Nagamura-Inoue, Tokiko

AU - Kato, Shunichi

AU - Sakamaki, Hisashi

AU - Morishima, Yasuo

AU - Okamura, Jun

AU - Ichinohe, Tatsuo

AU - Uchiyama, Takashi

PY - 2010/8/26

Y1 - 2010/8/26

N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used as a curative option for adult T-cell leukemia (ATL), an intractable mature T-cell neoplasm causally linked with human T-cell leukemia virus type I (HTLV-I). We compared outcomes of 386 patients with ATL who underwent allogeneic HSCT using different graft sources: 154 received human leukocyte antigen (HLA)-matched related marrow or peripheral blood; 43 received HLA-mismatched related marrow or peripheral blood; 99 received unrelated marrow; 90 received single unit unrelated cord blood. After a median follow-up of 41 months (range, 1.5-102), 3-year overall survival for entire cohort was 33% (95% confidence interval, 28%-38%). Multivariable analysis revealed 4 recipient factors significantly associated with lower survival rates: older age (> 50 years), male sex, status other than complete remission, and use of unrelated cord blood compared with use of HLA-matched related grafts. Treatment-related mortality rate was higher among patients given cord blood transplants; disease-associated mortality was higher among male recipients or those given transplants not in remission. Among patients who received related transplants, donor HTLV-I seropositivity adversely affected disease-associated mortality. In conclusion, allogeneic HSCT using currently available graft source is an effective treatment in selected patients with ATL, although greater effort is warranted to reduce treatment-related mortality.

AB - Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used as a curative option for adult T-cell leukemia (ATL), an intractable mature T-cell neoplasm causally linked with human T-cell leukemia virus type I (HTLV-I). We compared outcomes of 386 patients with ATL who underwent allogeneic HSCT using different graft sources: 154 received human leukocyte antigen (HLA)-matched related marrow or peripheral blood; 43 received HLA-mismatched related marrow or peripheral blood; 99 received unrelated marrow; 90 received single unit unrelated cord blood. After a median follow-up of 41 months (range, 1.5-102), 3-year overall survival for entire cohort was 33% (95% confidence interval, 28%-38%). Multivariable analysis revealed 4 recipient factors significantly associated with lower survival rates: older age (> 50 years), male sex, status other than complete remission, and use of unrelated cord blood compared with use of HLA-matched related grafts. Treatment-related mortality rate was higher among patients given cord blood transplants; disease-associated mortality was higher among male recipients or those given transplants not in remission. Among patients who received related transplants, donor HTLV-I seropositivity adversely affected disease-associated mortality. In conclusion, allogeneic HSCT using currently available graft source is an effective treatment in selected patients with ATL, although greater effort is warranted to reduce treatment-related mortality.

UR - http://www.scopus.com/inward/record.url?scp=77956511566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956511566&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-10-247510

DO - 10.1182/blood-2009-10-247510

M3 - Article

C2 - 20479287

AN - SCOPUS:77956511566

VL - 116

SP - 1369

EP - 1376

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -